Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Preparation of Competent Cells – V 2.0

Posted on By


Biosimilars: SOP for Preparation of Competent Cells – V 2.0


Standard Operating Procedure for Preparation of Competent Cells in Biosimilar R&D

Department Biosimilars
SOP No. SOP/BS/004/2025
Supersedes SOP/BS/004/2022
Page No. Page 1 of 11
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the process for preparing chemically and electrocompetent E. coli cells for use in transformation procedures during biosimilar molecular biology workflows.

2. Scope

This SOP applies to laboratory personnel involved in preparing and storing competent bacterial cells within the Biosimilars R&D facility.

3. Responsibilities

  • Research Associate: Carries out the competent cell preparation procedure and maintains documentation.
  • Laboratory Technician: Prepares media and buffers, ensures sterile conditions, and labels vials.
  • QA Officer: Verifies batch records and checks viability logs.
See also  Biosimilars: SOP for Agarose Gel Electrophoresis - V 2.0

4. Accountability

The Head of Molecular Biology is accountable for ensuring that all competent cell preparations meet quality and transformation efficiency requirements.

5. Procedure

5.1 Reagents and Materials Required

  • SOB medium or LB broth
  • Calcium chloride (CaCl2) solution (100 mM)
  • Glycerol (10%) for storage
  • Electroporation buffer (if preparing electrocompetent cells)
  • Ice, sterile tubes, centrifuge

5.2 Culture Growth

  1. Inoculate a single colony of E. coli DH5α into 5 mL LB broth and incubate overnight at 37°C with shaking (200 rpm).
  2. Dilute 1:100 into 100 mL fresh LB medium and grow until OD600 reaches 0.4–0.6.

5.3 Preparation of Chemically Competent Cells

  1. Chill the culture on ice for 10–15 minutes.
  2. Centrifuge at 4,000 rpm for 10 minutes at 4°C.
  3. Discard supernatant and gently resuspend pellet in 50 mL of ice-cold 100 mM CaCl2.
  4. Incubate on ice for 30 minutes.
  5. Repeat centrifugation and resuspend in 10 mL of ice-cold 100 mM CaCl2 + 15% glycerol.
  6. Aliquot 100 µL per sterile microcentrifuge tube and flash freeze in liquid nitrogen.
  7. Store at -80°C.
See also  Biosimilars: SOP for Transient Transfection Methods - V 2.0

5.4 Preparation of Electrocompetent Cells

  1. Harvest cells as above once OD600 reaches 0.5.
  2. Wash cells three times with ice-cold sterile 10% glycerol.
  3. Resuspend final pellet in 1 mL ice-cold 10% glycerol.
  4. Aliquot into pre-chilled sterile tubes (50 µL each) and store at -80°C.

5.5 Documentation and Quality Check

  1. Label all tubes with strain name, date, and preparation type (chemically/electrocompetent).
  2. Log entries in Competent Cell Preparation Log (Annexure-1).
  3. Test transformation efficiency using a standard plasmid (e.g., pUC19) and record in Transformation Efficiency Report (Annexure-2).

6. Abbreviations

  • SOP: Standard Operating Procedure
  • OD600: Optical Density at 600 nm
  • QA: Quality Assurance

7. Documents

  1. Competent Cell Preparation Log (Annexure-1)
  2. Transformation Efficiency Report (Annexure-2)
See also  Biosimilars: SOP for Colony Screening and Expression Analysis - V 2.0

8. References

  • ICH Q5A: Viral Safety Evaluation of Biotechnology Products
  • WHO Guidelines for Recombinant DNA Products
  • CDSCO Laboratory Practice Manual

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Competent Cell Preparation Log

Date Strain Type OD600 Stored At Prepared By
01/05/2025 E. coli DH5α Chemically Competent 0.45 -80°C Sunita Reddy

Annexure-2: Transformation Efficiency Report

Date Strain Plasmid Colonies Obtained Efficiency (cfu/µg DNA) Status
02/05/2025 E. coli DH5α pUC19 1200 6 × 106 Accepted

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Separated electrocompetent and chemical protocols Version update
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: SOP for Managing Temperature-Controlled Zones in Warehouses – V 2.0
Next Post: Creams: SOP for Adjusting Filling Nozzles for Precise Cream Dispensing – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version